Price$194.50+4.40 (+2.31%)
01:30 PM07:45 PM
News · 26 weeks77+114%
2025-11-022026-04-26
Mix6090d
- Insider39(65%)
- SEC Filings9(15%)
- Other7(12%)
- Earnings3(5%)
- Dividends1(2%)
- Offering1(2%)
Latest news
25 items- SECSEC Form FWP filed by Quest Diagnostics IncorporatedFWP - QUEST DIAGNOSTICS INC (0001022079) (Subject)
- PRQuest Diagnostics Prices $500 Million of Senior NotesSECAUCUS, N.J., April 27, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the "Notes") under Quest Diagnostics' shelf registration statement. Quest Diagnostics expects to receive the net offering proceeds upon closing on May 6, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering for general corporate
- INSIDERExecutive Vice President & CFO Samad Sam was granted 108 shares, increasing direct ownership by 0.32% to 33,376 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERSVP for Diagnostic Services Plewman Patrick increased direct ownership by 0.32% to 15,247 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERDirector Gregg Vicky B was granted 68 shares, increasing direct ownership by 0.40% to 17,172 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERDirector Carter Robert B increased direct ownership by 0.26% to 2,711 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERDirector Lassiter Wright Iii increased direct ownership by 0.07% to 9,063 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERSVP, Clinical Solutions Kuppusamy Karthik increased direct ownership by 0.29% to 13,490 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERSVP & Chief Commercial Officer Delaney Mark E increased direct ownership by 0.31% to 11,901 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- SECSEC Form 10-Q filed by Quest Diagnostics Incorporated10-Q - QUEST DIAGNOSTICS INC (0001022079) (Filer)
- SECQuest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
- PRQuest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growthFirst quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted diluted EPS of $2.50, up 13.1% from 2025Full year 2026 reported diluted EPS now expected to be between $9.58 and $9.78; and adjusted diluted EPS is expected to be between $10.63 and $10.83SECAUCUS, N.J., April 21, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.
- PRCity of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple CancersFourteen City of Hope sites across the U.S. participating in research using the Haystack MRD ctDNA Test in patients with breast, colorectal, ovarian, and prostate cancerSECAUCUS, N.J. and LOS ANGELES, April 16, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, today announced that City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, is implementing Haystack MRD®, a highly accurate circulating-tumor DNA (ctDNA) minimal residual disease (MRD) test, for clinical trial participants with solid tumor cancers to help guide disease management for patients being treated for breast,
- SECSEC Form DEFA14A filed by Quest Diagnostics IncorporatedDEFA14A - QUEST DIAGNOSTICS INC (0001022079) (Filer)
- SECSEC Form DEF 14A filed by Quest Diagnostics IncorporatedDEF 14A - QUEST DIAGNOSTICS INC (0001022079) (Filer)
- INSIDERSEC Form 4 filed by Wentworth Timothy C4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Quest Diagnostics IncorporatedSCHEDULE 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)
- PRQuest Diagnostics to Release First Quarter Financial Results on April 21, 2026SECAUCUS, N.J., March 19, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leader in diagnostic information services, announced today that it will report first quarter 2026 financial results on Tuesday, April 21, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on w
- SECQuest Diagnostics Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)
- PRQuest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of DirectorsSECAUCUS, N.J., March 12, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced that its board of directors has elected Timothy (Tim) Wentworth, a highly seasoned business leader, to serve as a director. Including Mr. Wentworth, the company's board has eleven members. "As a former CEO of several large, publicly traded healthcare organizations, Tim brings incredible leadership experience to the Quest board," said Jim Davis, chairman, CEO and president of Quest Diagnostics. "His depth in the many chan
- INSIDERSEC Form 3 filed by Quest Diagnostics Incorporated3 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERSEC Form 4 filed by Quest Diagnostics Incorporated4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERExecutive Vice President & CFO Samad Sam was granted 13,947 shares and covered exercise/tax liability with 7,720 shares, increasing direct ownership by 23% to 33,268 units (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDEREVP, Regional Businesses Doherty Catherine T. was granted 11,364 shares, covered exercise/tax liability with 5,806 shares and sold $1,146,115 worth of shares (5,558 units at $206.21) (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
- INSIDERSVP & General Counsel Prevoznik Michael E was granted 7,232 shares, covered exercise/tax liability with 3,354 shares and sold $799,682 worth of shares (3,878 units at $206.21) (SEC Form 4)4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)
DGX FAQ
6 questionsWhat does Quest Diagnostics Incorporated do?
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers...Where does DGX stock trade?
Quest Diagnostics Incorporated (DGX) is listed on NYSE.What sector and industry is DGX in?
Quest Diagnostics Incorporated operates in the Health Care sector, Medical Specialities industry.What are analysts saying about DGX?
Quest Diagnostics Incorporated has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2026-01-30.What companies are similar to DGX?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare DGX side-by-side with any of them on Quantisnow.How can I track DGX on Quantisnow?
Quantisnow aggregates Quest Diagnostics Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DGX to receive live email and push alerts on every new disclosure.